Armagan, B. Et Al. 2020. SECUKINUMAB IS FREQUENTLY PREFERRED IN MULTI ANTI-TNF RESISTANCE SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS. Annual European Congress of Rheumatology (EULAR) , (ELECTR NETWORK), 419-420.

Armagan, B., Kilic, L., Yardimci, G. K., Bilgin, E., Farisogullari, B., Bolek, E. C., ... Duran, E.(2020). SECUKINUMAB IS FREQUENTLY PREFERRED IN MULTI ANTI-TNF RESISTANCE SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS . Annual European Congress of Rheumatology (EULAR) (pp.419-420). , ELECTR NETWORK

Armagan, BERKAN Et Al. "SECUKINUMAB IS FREQUENTLY PREFERRED IN MULTI ANTI-TNF RESISTANCE SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS," Annual European Congress of Rheumatology (EULAR), ELECTR NETWORK, 2020

Armagan, BERKAN Et Al. "SECUKINUMAB IS FREQUENTLY PREFERRED IN MULTI ANTI-TNF RESISTANCE SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS." Annual European Congress of Rheumatology (EULAR) , ELECTR NETWORK, pp.419-420, 2020

Armagan, B. Et Al. (2020) . "SECUKINUMAB IS FREQUENTLY PREFERRED IN MULTI ANTI-TNF RESISTANCE SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS." Annual European Congress of Rheumatology (EULAR) , ELECTR NETWORK, pp.419-420.

@conferencepaper{conferencepaper, author={BERKAN ARMAĞAN Et Al. }, title={SECUKINUMAB IS FREQUENTLY PREFERRED IN MULTI ANTI-TNF RESISTANCE SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS}, congress name={Annual European Congress of Rheumatology (EULAR)}, city={}, country={ELECTR NETWORK}, year={2020}, pages={419-420} }